In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 John William Eikelboom
Speaker
John William Eikelboom
John William Eikelboom John William Eikelboom

McMaster University, Hamilton (Canada)

Specialities : Pharmacology and Pharmacotherapy , Atrial Fibrillation, Pharmacology and Pharmacotherapy

John Eikelboom, MBBS, MSc, FRCPC is Professor, Department of Medicine, McMaster University; Senior Investigator, Population Health Research Institute; and Haematologist at the Hamilton General Hospital, Ontario, Canada. He holds a Heart and Stroke Foundation Career Award and the Jack Hirsh/Population Health Research Institute Chair in Thrombosis and Atherosclerosis. His research funded by peer-reviewed grants from the Heart and Stroke Foundation, Canadian Institutes for Health Research, and the National Health and Medical Research Council of Australia focuses on novel approaches to preventing and treating thromboembolism and bleeding. Dr Eikelboom has co-authored more than 600 articles in peer-reviewed journals, and since 2014 has been listed annually among the top 1% of the most cited researchers globally in Clinical Medicine.

41 presentations from this speaker

Panel discussion and audience questions: NOACs in cardiology settings.

Event : ESC Congress 2020

  • Session : NOACs in patients with atrial fibrillation: insights from the cardiac cath lab
  • Speaker : J Eikelboom (Hamilton,CA), DJ Angiolillo (Jacksonville,US)
  • Sponsored by Boehringer Ingelheim

Practical tips on uninterrupted NOACs in atrial fibrillation ablation.

Event : ESC Congress 2020

  • Session : NOACs in patients with atrial fibrillation: insights from the cardiac cath lab
  • Speaker : D Gupta (Liverpool,GB), J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

Setting the scene: safety, efficacy, and reversal.

Event : ESC Congress 2020

  • Session : NOACs in patients with atrial fibrillation: insights from the cardiac cath lab
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - PRO.

Event : ESC Congress 2019

  • Session : Controversies in antithrombotic treatment for primary and secondary prevention
  • Speaker : J Eikelboom (Hamilton,CA)

Case clinic: treatment choices in patients with chronic CAD and diabetes

Event : ESC Congress 2019

  • Session : Vascular protection: practical insights
  • Speaker : R Welsh (Edmonton,CA), J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer AG

Case clinic: why is risk stratification important?

Event : ESC Congress 2019

  • Session : Vascular protection: practical insights
  • Speaker : J Eikelboom (Hamilton,CA), R Welsh (Edmonton,CA)
  • Sponsored by Bayer AG

Intensified antithrombotic treatment for chronic coronary artery disease - Applying the data to your patients

Event : ESC Congress 2019

  • Session : Vascular protection - Which of your patients with chronic coronary artery disease will benefit?
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer AG

Introduction: celebrating a decade of innovation in atrial fibrillation

Event : ESC Congress 2019

  • Session : 10 years since RE-LY: comprehensive experience for atrial fibrillation patients
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

Quickfire questions and answers: anticoagulation in atrial fibrillation patients with cardiac comorbidities

Event : ESC Congress 2019

  • Session : 10 years since RE-LY: comprehensive experience for atrial fibrillation patients
  • Speaker : J Eikelboom (Hamilton,CA), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Quickfire questions and answers: anticoagulation in atrial fibrillation patients with comorbidities

Event : ESC Congress 2019

  • Session : 10 years since RE-LY: comprehensive experience for atrial fibrillation patients
  • Speaker : J Eikelboom (Hamilton,CA), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Quickfire questions and answers: NOAC safety profiles

Event : ESC Congress 2019

  • Session : 10 years since RE-LY: comprehensive experience for atrial fibrillation patients
  • Speaker : J Eikelboom (Hamilton,CA), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Welcome and introduction

Event : ESC Congress 2019

  • Session : Vascular protection: practical insights
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer AG

Antithrombotic therapy in stable cardiovascular disease - Represented in NEJM by the COMPASS trial and the PEGASUS-TIMI 54 trial

Event : ESC Congress 2018

  • Session : Highlights from the New England Journal of Medicine: Editors’ Choice
  • Speaker : J Eikelboom (Hamilton,CA)
  • Organised with the New England Journal of Medicine

Arterial disease and cardiovascular health: assessing the totality of NOAC Data .

Event : ESC Congress 2018

  • Session : New concepts in vascular protection: exploring the role of antithrombotic therapy
  • Speaker : J Eikelboom (Hamilton,CA)
  • Organised by Medscape Education, supported by an unrestricted grant provided by BAYER

Arterial disease and cardiovascular health: assessing the totality of NOAC data.

Event : ESC Congress 2018

  • Session : New concepts in vascular protection: exploring the role of antithrombotic therapy
  • Speaker : J Eikelboom (Hamilton,CA)
  • Organised by Medscape Education, supported with an educational grant from BAYER AG

How to manage patients with chronic coronary artery disease and peripheral artery disease.

Event : ESC Congress 2018

  • Session : Setting the COMPASS into new directions - Reducing risk in coronary artery disease and peripheral artery disease
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer AG

Improved outcomes for patients with chronic coronary artery disease and peripheral artery disease

Event : ESC Congress 2018

  • Session : Setting the COMPASS into new directions - Who will benefit most in coronary artery disease?
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer AG

Improved outcomes for patients with chronic Coronary Artery Disease and Peripheral Artery Disease

Event : ESC Congress 2018

  • Session : Setting the COMPASS into new directions
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer AG

NOACs and reversal: let’s discuss our clinical experience.

Event : ESC Congress 2018

  • Session : NOACs and reversal: let’s discuss our clinical experience
  • Speaker : J Eikelboom (Hamilton,CA), A Tomaszuk-Kazberuk (Bialystok,PL)
  • Sponsored by Boehringer Ingelheim

Audience Q&A - Anticoagulation care: covering all the bases.

Event : ESC Congress 2017

  • Session : Anticoagulation care: covering all the bases
  • Speaker : J Halperin (New York,US), J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial: Primary Results

Event : ESC Congress 2017

  • Session : Hot Line: Late-Breaking Clinical Trials 1
  • Speaker : J Eikelboom (Hamilton,CA)

Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial: Primary Results.

Event : ESC Congress 2017

  • Session : Meet the Trialists - COMPASS
  • Speaker : J Eikelboom (Hamilton,CA)

Closing remarks - Vascular protection in CAD and PAD through factor Xa inhibition... The COMPASS study.

Event : ESC Congress 2017

  • Session : Vascular protection in coronary artery disease (CAD) and peripheral artery disease (PAD) through factor Xa inhibition... The COMPASS study
  • Speaker : SJ Connolly (Hamilton,CA), J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer AG

Coronary artery disease and peripheral artery disease: exploring new indications.

Event : ESC Congress 2017

  • Session : NOACs and new frontiers in anticoagulation management
  • Speaker : J Eikelboom (Hamilton,CA)
  • Organised by Medscape Education, supported with an educational grant by Bayer

Dabigatran reversal when the unexpected happens.

Event : ESC Congress 2017

  • Session : Anticoagulation care: covering all the bases
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

Interactive discussions and questions - Vascular protection in CAD and PAD through factor Xa inhibition... The COMPASS study.

Event : ESC Congress 2017

  • Session : Vascular protection in coronary artery disease (CAD) and peripheral artery disease (PAD) through factor Xa inhibition... The COMPASS study
  • Speaker : D Bhatt (Newton,US), P Steg (Paris,FR), J Eikelboom (Hamilton,CA), SJ Connolly (Hamilton,CA), S Yusuf (Hamilton,CA)
  • Sponsored by Bayer AG

NOACs and new frontiers in anticoagulation management.

Event : ESC Congress 2017

  • Session : NOACs and new frontiers in anticoagulation management
  • Speaker : M Patel (Durham,US), J Eikelboom (Hamilton,CA), K Fox (Edinburgh,GB), F Verheugt (Amsterdam,NL)
  • Organised by Medscape Education, supported with an educational grant by Bayer

The COMPASS study... From start to stop.

Event : ESC Congress 2017

  • Session : Vascular protection in coronary artery disease (CAD) and peripheral artery disease (PAD) through factor Xa inhibition... The COMPASS study
  • Speaker : SJ Connolly (Hamilton,CA), J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer AG

The COMPASS study... Vascular protection with rivaroxaban in patients with CAD or PAD.

Event : ESC Congress 2017

  • Session : Exploring vascular protection in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) through the potential of factor Xa inhibition... The COMPASS study
  • Speaker : SJ Connolly (Hamilton,CA), J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer AG

Case 3 – How long is long enough?

Event : ESC Congress 2016

  • Session : Developing real-world patient pathways in acute pulmonary embolism
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Bayer Pharma AG

NOACs: where are we going?

Event : ESC Congress 2016

  • Session : Oral anticoagulation + specific reversal = more control
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

Reversal agents for NOACs: what's available and how do they work?

Event : ESC Congress 2016

  • Session : Reversal agents for NOACs: what's available and how do they work?
  • Speaker : J Halperin (New York,US), J Weitz (Hamilton,CA), J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

Enhancing patient care with oral anticoagulation.

Event : ESC Congress 2015

  • Session : Navigating the universe of anticoagulation in stroke prevention and venous thromboembolism
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by BMS-Pfizer Alliance

Panel discussion and Q&A - The new world of anticoagulation: NOACs in 2015 and beyond.

Event : ESC Congress 2015

  • Session : The new world of anticoagulation: NOACs in 2015 and beyond
  • Speaker : J Eikelboom (Hamilton,CA), HC Diener (Essen,DE)
  • Sponsored by Boehringer Ingelheim

Welcome to the new world of anticoagulation.

Event : ESC Congress 2015

  • Session : The new world of anticoagulation: NOACs in 2015 and beyond
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

Considering the bigger picture: practical insights for patient management.

Event : ESC Congress 2014

  • Session : Practical patient protection: celebrating the benefits of dabigatran 5 years on from RE-LY®
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

Role of the physician in the prescription and interpretation of laboratory testing in patients treated with new oral anticoagulants.

Event : ESC Congress 2014

  • Session : Coagulation assessment in patients treated with novel oral anticoagulants: new developments and practical guidance
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Diagnostica Stago / Bayer HealthCare / Daiichi Sankyo / Boehringer Ingelheim / Bristol-Myers Squibb and Pfizer Alliance

Anticoagulants: which one for which patient?

Event : ESC Congress 2013

  • Session : Atrial fibrillation treatment in 2013
  • Speaker : J Eikelboom (Hamilton,CA)

Optimizing periprocedural protection with novel oral anticoagulants.

Event : ESC Congress 2013

  • Session : Practical guidance for stroke prevention in atrial fibrillation - Interactive case studies
  • Speaker : J Eikelboom (Hamilton,CA)
  • Sponsored by Boehringer Ingelheim

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are